Transitioning from preclinical to clinical chemopreventive assessments of lyophilized black raspberries: interim results show berries modulate markers of oxidative stress in Barrett's esophagus patients.
Increased fruit and vegetable consumption is associated with decreased risk of a number of cancers of epithelial origin, including esophageal cancer. Dietary administration of lyophilized black raspberries (LBRs) has significantly inhibited chemically induced oral, esophageal, and colon carcinogenesis in animal models. Likewise, berry extracts added to cell cultures significantly inhibited cancer-associated processes. Positive results in preclinical studies have supported further investigation of berries and berry extracts in high-risk human cohorts, including patients with existing premalignancy or patients at risk for cancer recurrence. We are currently conducting a 6-mo chemopreventive pilot study administering 32 or 45 g (female and male, respectively) of LBRs to patients with Barrett's esophagus (BE), a premalignant esophageal condition in which the normal stratified squamous epithelium changes to a metaplastic columnar-lined epithelium. BE's importance lies in the fact that it confers a 30- to 40-fold increased risk for the development of esophageal adenocarcinoma, a rapidly increasing and extremely deadly malignancy. This is a report on interim findings from 10 patients. To date, the results support that daily consumption of LBRs promotes reductions in the urinary excretion of two markers of oxidative stress, 8-epi-prostaglandin F2alpha (8-Iso-PGF2) and, to a lesser more-variable extent, 8-hydroxy-2'-deoxyguanosine (8-OHdG), among patients with BE.
Kresty
Laura A
LA
Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus 43210, USA. kresty.1@osu.edu
Frankel
Wendy L
WL
Hammond
Cynthia D
CD
Baird
Maureen E
ME
Mele
Jennifer M
JM
Stoner
Gary D
GD
Fromkes
John J
JJ
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage; D001471:Barrett Esophagus / Q000150:complications / Q000628:therapy*; D015415:Biomarkers / Q000032:analysis; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D004938:Esophageal Neoplasms / Q000517:prevention & control*; D005260:Female; D005519:Food Preservation; D005612:Freeze Drying; D005638:Fruit / Q000737:chemistry; D005764:Gastroesophageal Reflux / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D008517:Phytotherapy; D010865:Pilot Projects; D011230:Precancerous Conditions; D027824:Rosaceae / Q000737:chemistry
D016588:Anticarcinogenic Agents; D015415:Biomarkers; C075750:8-epi-prostaglandin F2alpha; D000080242:8-Hydroxy-2'-Deoxyguanosine; D015237:Dinoprost; D003849:Deoxyguanosine